Clinical Trial Update: A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma [Phase 2]

View source ↗

Summary

Phase 2 study updating pembrolizumab with olaparib in endometrial carcinosarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Cancer
• Endometrial Carcinosarcoma

Drugs mentioned

• Olaparib (Olaparib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Endometrial Carcinosarcoma | Phase 2 | Status: COMPLETED